These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22158616)

  • 21. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.
    Segouffin-Cariou C; Billaud M
    J Biol Chem; 2000 Feb; 275(5):3568-76. PubMed ID: 10652352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR.
    Gonçalves AP; Videira A; Soares P; Máximo V
    Life Sci; 2011 Sep; 89(11-12):371-7. PubMed ID: 21807000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies.
    Muzza M; Degl'Innocenti D; Colombo C; Perrino M; Ravasi E; Rossi S; Cirello V; Beck-Peccoz P; Borrello MG; Fugazzola L
    Clin Endocrinol (Oxf); 2010 May; 72(5):702-8. PubMed ID: 20447069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors.
    De Falco V; Guarino V; Malorni L; Cirafici AM; Troglio F; Erreni M; Pelicci G; Santoro M; Melillo RM
    Oncogene; 2005 Sep; 24(41):6303-13. PubMed ID: 15940252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.
    Melillo RM; Castellone MD; Guarino V; De Falco V; Cirafici AM; Salvatore G; Caiazzo F; Basolo F; Giannini R; Kruhoffer M; Orntoft T; Fusco A; Santoro M
    J Clin Invest; 2005 Apr; 115(4):1068-81. PubMed ID: 15761501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
    Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
    Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.
    Mazumdar M; Adhikary A; Chakraborty S; Mukherjee S; Manna A; Saha S; Mohanty S; Dutta A; Bhattacharjee P; Ray P; Chattopadhyay S; Banerjee S; Chakraborty J; Ray AK; Sa G; Das T
    Apoptosis; 2013 May; 18(5):589-604. PubMed ID: 23329180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
    Besset V; Scott RP; Ibáñez CF
    J Biol Chem; 2000 Dec; 275(50):39159-66. PubMed ID: 10995764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.
    Sheils OM; O'Leary JJ; Sweeney EC
    J Pathol; 2000 Sep; 192(1):32-6. PubMed ID: 10951397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
    Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
    Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages.
    Mukundan L; Bishop GA; Head KZ; Zhang L; Wahl LM; Suttles J
    J Immunol; 2005 Jan; 174(2):1081-90. PubMed ID: 15634933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho.
    Barone MV; Sepe L; Melillo RM; Mineo A; Santelli G; Monaco C; Castellone MD; Tramontano D; Fusco A; Santoro M
    Oncogene; 2001 Oct; 20(48):6973-82. PubMed ID: 11704822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.
    Miller KA; Yeager N; Baker K; Liao XH; Refetoff S; Di Cristofano A
    Cancer Res; 2009 Apr; 69(8):3689-94. PubMed ID: 19351816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.
    Castellone MD; Cirafici AM; De Vita G; De Falco V; Malorni L; Tallini G; Fagin JA; Fusco A; Melillo RM; Santoro M
    Oncogene; 2003 Jan; 22(2):246-55. PubMed ID: 12527893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative.
    Lanzi C; Cassinelli G; Pensa T; Cassinis M; Gambetta RA; Borrello MG; Menta E; Pierotti MA; Zunino F
    Int J Cancer; 2000 Feb; 85(3):384-90. PubMed ID: 10652431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
    Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM
    Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
    Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
    Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
    Chen Z; Sasaki T; Tan X; Carretero J; Shimamura T; Li D; Xu C; Wang Y; Adelmant GO; Capelletti M; Lee HJ; Rodig SJ; Borgman C; Park SI; Kim HR; Padera R; Marto JA; Gray NS; Kung AL; Shapiro GI; Jänne PA; Wong KK
    Cancer Res; 2010 Dec; 70(23):9827-36. PubMed ID: 20952506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.